Peer-Reviewed Article
1. Chang YC#, Chan MH, Yang YF, Li CH, Hsiao M. Glucose transporter 4: Insulin response mastermind, glycolysis catalyst and treatment direction for cancer progression. Cancer Lett. 2023. 216179. doi:10.1016/j.canlet.2023.216179. # 1st author.
2. Yang YF, Tsai KW, MH Peter Chang, Chang YC*. Editorial: Metabolism-based Omics Integrations, Biosensors, and Molecular Mechanisms in Human Cancers. Front Oncol. 2023. 13:1159545. Doi:10.3389/fonc.2023.1159545. *Corresponding author
3. Chang YC#, Li CH#, Chan MH, Fang CY, Zhang ZX, Chen CL, Hsiao M. Overexpression of synaptic vesicle protein Rab GTPase 3C promotes vesicular exocytosis and drug resistance in colorectal cancer cells. Mol Oncol. 2023. 17(3):422-444. doi: 10.1002/1878-0261.13378. # co-1st author.
4. Li CH, Fang CY, Chan MH, Chen CL, Chang YC*, Hsiao M. The cytoplasmic expression of FSTL3 correlates with colorectal cancer progression, metastasis status and prognosis. J Cell Mol Med. 2023. Feb 18. doi: 10.1111/jcmm.17690. *Corresponding author
5. Li CH, Fang CY, Chan MH, Lu PJ, Ger LP, Chu JS, Chang YC*, Chen CL, Hsiao M. The activation of EP300 by F11R leads to EMT and acts as a prognostic factor in triple-negative breast cancer. J Pathol Clin Res. 2023. Feb 13. doi: 10.1002/cjp2.313. *Corresponding author
6. Chung SY, Chang YC*, Hsu SS, Hung YC, Lu ML, Hung YP, Chiang NJ, Yeh CN, Hsiao M, Soong J, Su Y, Chen MH. A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer. Neoplasia. 2023. 35:100856. doi: 10.1016/j.neo.2022.100856. *co-1st author
7. Li CH, Chang MH, Chang YC, Hsiao M. Gold Nanoparticles ad a Biosensor for Cancer Biomarker Determination. Molecules. 2023. 28(1):364. doi: 10.3390/molecules28010364. (Invited Review)
8. Chan MH, Li CH, Chang YC, Hsiao M. Iron-Based Ceramic Composite Nanomaterials for Magnetic Fluid Hyperthermia and Drug Delivery. Pharmaceutics. 2022. 14(12):2584. doi: 10.3390/pharmaceutics14122584. (Invited Review)
9. Yang YF, Li CH, Cai HY, Lin BS, Kim CH, Chang YC*. Application of Metabolic Reprogramming to Cancer Imaging and Diagnosis. Int J Mol Sci. 2022. 23(24):15831. doi: 10.3390/ijms232415831. *Corresponding author (Invited Review)
10. Li CH, Chang YC, Chan MH, Hsiao M. Ultrasound and Nanomedicine for Cancer-Targeted Drug Delivery: Screening, Cellular Mechanisms and Therapeutic Opportunities. Pharmaceutics. 2022. 14(6):1282. doi: 10.3390/pharmaceutics14061282. (Invited Review)
11. Fukushi A, Kim HD, Chang YC*, Kim CH. Revisited Metabolic Control and Reprogramming Cancers by Means of the Warburg Effect in Tumor Cells. Int J Mol Sci. 2022. 23(17):10037. doi: 10.3390/ijms231710037. *Corresponding author (Invited Review)
12. Li CH, Chan MH, Chang YC, Hsiao M. The CHST11 gene is linked to lung cancer and pulmonary fibrosis. J Gene Med. 2022. 24(12):e3451. doi: 10.1002/jgm.3451.
13. Chang WM, Li LJ, Chiu IA, Lai TC, Chang YC, Tsai HF, Yang CJ, Huang MS, Su CY, Lai TL, Jan YH, Hsiao M. The aberrant cancer metabolic gene carbohydrate sulfotransferase 11 promotes non-small cell lung cancer cell metastasis via dysregulation of ceruloplasmin and intercellular iron balance. Transl Oncol. 2022. 25:101508. doi: 10.1016/j.tranon.2022.101508.
14. Yang YF, Chang YC, Tsai KW, Hung MH, Kang BH. J Cell Mol Med. 2022. 26(13):3716-3725. doi: 10.1111/jcmm.17400.
15. Li CH, Chan MH, Liang SM, Chang YC*, Hsiao M. Fascin-1: Updated biological functions and therapeutic implications in cancer biology. BBA Advances. 2022, 10052. doi.org/10.1016/j.bbadva.2022.100052. *Corresponding author (Invited Review)
16. Chang YC, Kim CH. Molecular Research of Glycolysis. Int J Mol Sci. 2022. 23(9):5052. doi: 10.3390/ijms23095052. *Corresponding author (Invited Review_Editorial)
17. Chang YC, Li CH, Chan MH, Chen MH, Yeh CN, Hsiao M. Regorafenib Inhibits Epithelial-Mesenchymal Transition and Suppresses Cholangiocarcinoma Metastasis. Cell Death & Disease. 2022, 13(4):391. doi: 10.1038/s41419-022-04816-7.
18. Li CH, Chan MH, Chang YC*. The role of fructose 1,6-bisphosphate-mediated glycolysis/gluconeogenesis genes in cancer prognosis. Aging. 2022, 14(7):3233-3258. doi: 10.18632/aging.204010. *Corresponding author
19. Chen HW, Lin MC, Wu PR, Chang YC, Weng SS, Tsai WC. Prostaglandin F2 Receptor Inhibitor Overexpression Predicts Advanced WHO Grades and Adverse Prognosis in Human Glioma Tissue. Chin J Physiol. 2022, 65(2):93-102. doi: 10.4103/cjp.cjp_97_21.
20. Li LJ, Chang MH, Li CH, Chang YC, Lai TC, Su CY, Chen CL, Chang WM, Hsiao M, Feng SW. FAS receptor regulates NOTCH activity through ERK-JAG1 axis activation and controls oral cancer stemness ability and pulmonary metastasis. Cell Death Discovery. 2022, 8(1):101. doi: 10.1038/s41420-022-00899-5.
21. Lee YC, Tsai KW, Liao JB, Kuo WT, Chang YC, Yang YF. High expression of tight junction protein 1 as a predictive biomarker for bladder cancer grade and staging. Sci Rep. 2022, 12(1):1496. doi: 10.1038/s41598-022-05631-y.
22. Chang YC, Chang MH, Li CH, Chan MH, Lee YJ, Chen MH, Hsiao M. Aldolase A and Phospholipase D1 Synergistically Resist Alkylating Agents and Radiation in Lung Cancer. Front Oncol. 2021, 11:811635. Doi: 10.3389/fonc.2021.811635.
23. Chang ZX, Li CH, Chang YC, Huang CY, Chang MH, Hsiao M. Novel Monodisperse FePt Nanocomposites for T2-Weighted Magnetic Resonance Imaging: Biomedical Theranostics Applications. Nanoscale Adv. 2022, 4:377-386. doi: 10.1039/D1NA00613D
24. Lin MY, Chang YC, Wang SY, Yang MH, Chang CH, Hsiao M, Richard Kitsis, Lee YJ. OncomiR miR-182-5p Enhances Radiosensitivity by Inhibiting the Radiation-Induced Antioxidant Effect through SESN2 in Head and Neck Cancer. Antioxidants. 2021, 10(11):1808. doi: 10.3390/antiox10111808.
25. Tsai HF*, Chang YC*, Li CH, Chan MH, Chen CL, Tsai WC, Hisao M. Type V collagen alpha 1 chain promotes the malignancy of glioblastoma through PPRC1-ESM1 axis activation and extracellular matrix remodeling. Cell Death Discovery. 2021, 7(1):313. doi: 10.1038/s41420-021-00661-3. *co-1st author
26. Yang YF, Chuang HW, Kuo WT, Lin BS, Chang YC*. Current Development and Application of Anaerobic Glycolytic Enzymes in Urothelial Carcinoma. Int J Mol Sci. 2021, 22(19):10612. doi: 10.3390/ijms221910612. Invited Review. *Corresponding author
27. Chan MH, Lu CN, Chung YL, Chang YC, Li CH, Chen CL, Wei DH, Hsiao M. Magnetically Guided Theranostics: Montmorillonite-Based Iron/Platinum Nanoparticles for Enhancing in Situ MRI Contrast and Hepatocellular Carcinoma Treatment. J Nanobiotechnology. 2021, 19(1):308. doi: 10.1186/s12951-021-01052-7.
28. Li HC, Hsu TI, Chang YC, Chan MH, Lu PJ, Hsiao M. Stationed or Relocating: The Seesawing EMT/MET Determinants from Embryonic Development to Cancer Metastasis. Biomedicines. 2021, 9(9):1265. doi: 10.3390/biomedicine9091265. Invited Review.
29. Li HC*, Chang YC*, Chan MH, Yang YF, Liang SM, Hsiao M. Galectins in Cancer and the Microenvironment: Functional Roles, Therapeutic Developments, and Perspectives. Biomedicines. 2021, 9(9):1159. doi: 10.3390/biomedicine9091159. Invited Review. *co-1st author
30. Chang YC, Chan MH, Li CH, Fang CY, Hsiao M, Chen CL. Exosomal Components and Modulators in Colorectal Cancer: Novel Diagnosis and Prognosis Biomarkers. Biomedicines. 2021, 9(8):931. doi: 10.3390/biomedicines9080931. Invited Review.
31. Chung SY, Hung YP, Pan YR, Chang YC, Wu CE, Hsu SS, Chang MH, Lu ML, Huang CY, Su Y, Hsiao M, Yeh CN, Chen MH*. Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. Biomedicines. 2021, 9(8):885. doi: 10.3390/biomedicines9080885.
32. Chan MH, Chen W, Li CH, Fang CY, Chang YC, Wei DH, Liu RS, Hsiao M*. Advanced In Situ MRI and Ultrasonic Theranostics Nanocomposite Platform: Crossing the Blood-Brain Barrier and Improving the Suppression of Glioblastoma Using Iron-Platinum Nanoparticles in Nanobubbles, ACS Appl Mater Interfaces, 2021, 13(23):26759-26769. doi:10.1021/acsami.1c04990.
33. Chang YC, Chan MH, Li CH, Yang CJ, Tseng YW, Tsai HF, Chiou J, Hsiao M*. Metabolic Protein Phosphoglycerate Kinase 1 Confers Lung Cancer Migration by Directly Binding HIV Tat Specific Factor 1, Cell Death Discov. 2021, 7(1), 135. doi: 10.1038/s41420-021-00520-1.
34. Hu YF, Wu CH, Lai TC, Chang YC, Hwang MJ, Chang TY, Wen CH, Chang PM, Chen CH, Mochly-Rosen D, Huang CF, Chen SA. ALDH2 deficinecy induces atrial fibrillation through dysregulated cardiac sodium channel and mitochondrial bioenergetics: A multi-omics analysis. Biochim Biophys Acta Mol Basis Dis. 2021, 1867(5):166088. doi: 10.1016/j.bbadis. 2021.166088.
35. Chen CL, Chen CC, Yu WH, Chen SH, Chang YC, Hsu TI, Hsiao M, Yeh CY, Chen CY. An annotation –free whole-slide training approach to pathological classification of lung cancer types using deep learning. Nat Commun. 2021, 12(1):1193. doi:10.1038/s41467-021-21467-y.
36. Pan KF, Lee WJ, Chou CC, Yang YC, Chang YC, Chien MH, Hsiao M, Hua KT. Direct interaction of β-catenin with nuclear ESM1 supports stemness of metastatic prostate cancer. EMBO J. 2021, 40(4):e105450. doi: 10.15252/embj.2020105450
37. Fang CY, Lai TC, Hsiao M and Chang YC*. The Diverse Roles of TAO kinases in Health and Diseases. Int. J. Mol. Sci. 2020, 21(20), E7463. doi:10.3390/ijms21207463. doi: 10.3390/ijms21207463. Invited Review.
38. Chang YC, Chen MH, Yeh CN and Hsiao M. Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma. Biomolecules. 2020 Sep 28;10(10): E1377. doi:10.3390/biom10101377. doi: 10.3390/biom10101377. Invited Review.
39. Tsai YL, Chang HH, Chen YC, Chang YC, Chen Y, Tsai WC. Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance. Biomedicines. 2020, 8(9):339. doi: 10.3390/biomedicines8090339.
40. Yang YF, Chang YC*, Jan YH, Yang CJ, Huang MS, Hsiao M*. Squalene synthase promotes the invasion of lung cancer cells via the osteopontin/ERK pathway. Oncogenesis 2020, 9(8):78. doi:10.1038/s41389-020-00262-2. *co-corresponding authors.
41. Yang YF, Wang YY, Hsia M, Lo S, Chang YC, Jan YH, Lai TC, Lee YC, Hsieh YC and Yuan SF. IMPAD1 functions as mitochondrial electron transport inhibitor that prevents ROS production and promotes lung cancer metastasis through the AMPK-Nothch1-HEY1 pathway. Cancer Lett. 2020 Aug 10;485:27-37. doi: 10.1016/j.canlet.2020.04.025.
42. Chang YC, Yang YF, Chiou J, Tsai HF, Fang CY, Yang CJ, Chen CL and Hsiao M. Nonenzymatic function of Aldolase A downregulates miR-145 to promote the Oct4/DUSP4/TRAF4 axis and the acquisition of lung cancer stemness. Cell Death Dis. 2020, 11(3):195. Doi:10.1038/s41419-020-2387-2.
43. Tan KT, Yeh CN, Chang YC, Cheng JH, Fang WL, Yeh YC, Wang YC, Hsu DS, Wu CE, Lai JI, Chang PM, Chen MH, Lu ML, Chen SJ, Chao Y, Hsiao M and Chen MH. PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy. J Immunother Cancer. 2020, 8(1). Pii: e000485. Doi: 10.1136/jitc-2019-000485.
44. Chan YC#, Chang YC#, Chuang HH#, Yang YC, Lin YF, Huang MS, Hsiao M*, Yang CJ* and Hua KT*. Overexpression of PSAT1 promotes metastasis of lung adenocarcinoma by suppressing the IRF1-IFN gamma axis. Oncogene. 2020, 39(12):2509-2522 Doi:1038/s41388-020-1160-4. *co-1st author
45. Li CH, Chang YC, Hsiao M, Liang SM. FOXD1 and Gal-3 Form a Positive Regulatory Loop to Regulate Lung Cancer Aggressiveness. Cancers (Basel). 2019 Nov 28;11(12). Pii: E1897. Doi: 10.3390/cancers1121897.
46. Chiou J#, Chang YC#, Tsai HF, Lin YF, Huang MS, Yang CJ, Hsiao M*. Follistatin-like protein 1 modulates osteopontin functional activation through direct protein interaction to suppress ILK signaling-induced lung cancer metastasis. Cancer Res. 2019. *co-1st author
47. Chiou J#, Chang YC#, Jan YH, Tsai HF, Yang CJ, Huang MS, Yu YL*, Hsiao M*. Overexpression of BZW1 is an independent poor prognosis marker and its down-regulation suppresses lung adenocarcinoma metastasis. Sci Rep. Accepted Sep. 18. #co-1st author.
48. Chang YC, Tsai HF, Chen CL, Hsiao M, Tsai WC. Enrichment of Aldolase C Correlates with Low Non-Mutated IDH1 Expression and Predicts a Favorable Prognosis in Glioblastomas. Cancers (Basel). 2019 Aug 23;11(9). pii: E1238. doi: 10.3390/cancers11091238.
49. Chang YC, Chiou J, Yang YF, Su CY, Lin YF, Yang CN, Lu PJ, Huang MS, Yang CJ, Hsiao M. Therapeutic Targeting of Aldolase A Interactions Inhibits Lung Cancer Metastasis and Prolongs Survival. Cancer Res. 2019 Sep 15;79(18):4754-4766. DOI: 10.1158/0008-5472.
50. Huang YJ*, Jan YH*, Chang YC*, Tsai HF, Wu TH Alexander, Chen CL, Hsiao M. ATP Synthase Subunit Epsilon Overexpression Promotes Metastasis by Modulating AMPL Signaling to Induce Epithelial-to-Mesenchymal Transition and Is a Poor Prognostic Marker in Colorectal Cancer Patients. J. Clin. Med. 2019, 8(7), 1070. *co-1st author
51. Tien CP, Chen CH, Lin WY, Liu CS, Liu KJ, Hsiao M, Chang YC*, Hung SC*. Ambient particulate matter attenuates Sirtuin 1 and augments SREBP1-PIR axis to induce human pulmonary fibroblast inflammation: molecular mechanism of microenvironment associated with COPD. Aging. 2019 Jul 12;11(13):4654-4671. doi: 10.18632/aging.102077. *co-corresponding author
52. Chang WM, Chang YC, Yang YC, Lin SK, Chang PM, Hsiao M. AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through crosstalk with the STAT1/3 signaling pathway. J Exp Clin Cancer Res. 2019 Jun 10;38(1):245.
53. Chang CY, Chang SL, Leu JD, Chang YC, Hsiao M, Lin LT, Lee YJ. Comparison of cofilin-1 and Twist-1 protein expression in human non-small cell lung cancer tissues. Oncol Rep. 2019 Jun 10.
54. Yeh CN, Chen MH, Chang YC, Wu RC, Tsao LC, Wang SY, Cheng CT, Chiang KC, Chen TW, Hsiao M, Weng WH. Over-expression of TNNI3K is associated with early-stage carcinogenesis of cholangiocarcinoma. Mol Carcinog. 2019 Feb;58(2):270-278.
55. Chang YC, Yang YC, Tien CP, Yang CJ, Hsiao M. Roles of aldolase family genes in human cancers and diseases. Trends Endocrinol Metab. 2018 Jun 12. pii: S1043-2760(18)30108-5.
56. Lin TC, Yeh YM, Fan WL, Chang YC, Lin WM, Yang TY, Hsiao M. Ghrelin Upregulates Oncogenic Aurora A to Promote Renal Cell Carcinoma Invasion. Oncotarget. 2018 Mar 30;9(24):17210-17219.
57. Yang YC, Chien MH, Liu HY, Chang YC, Chen CK, Lee WJ, Kuo TC, Hsiao M, Hua KT, Cheng TY. Nuclear translocation of PKM2/AMPK complex sustains cancer stem cell populations under glucose depletion stress. Cancer Lett. 2018 May 1;421:28-40.
58. Lin TC, Huang KW, Liu CW, Chang YC, Lin WM, Yang TY, Hsiao M. Leptin signaling axis associates with clinical prognosis and is multifunctional in regulating cancer progression. Oncotarget. 2018 Mar 30;9(24):17210-17219.
59. Yeh CN#, Chang YC#, Hsu DS, Lu ML, Liu CY, Chang PM, Chen MH, Huang CY, Hsiao M, Chen MH. Regorafenib inhibits MALT1 expression through RAF/ERK/Elk-1 pathway in cholangiocarcinoma. Oncotarget. 2017 Dec. 8;8(69):113444-113459. #co-1st author
60. Huang SP, Chang YC, Low QH, Wu ATH, Chen CL, Lin YF, Hsiao M. accepted, “BICD1 expression, 1 as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas”, Oncotarget, 2017 Nov. 27;8(69):113766-113791.
61. Chang YC, Chan YC, Chang MW, Lin YF, Yang CJ, Su CY, Huang MS, Wu AT, Hsiao M*. Feedback regulation of ALDOA activates HIF-1α/MMP9 axis to promote lung cancer progression. Cancer Letters, 2017, 403, 28-36.
62. Chi LH, Chang WM, Chang YC, Chan YC, Tai CC, Ger LP, Chen CL, Wu ATH, Lai TC, Li YCJ Li, Hsiao M. Global proteomics-based identification and validation of Thymosin beta-4 X-linked as a prognostic marker for head and neck squamous cell carcinomas. Sci Rep. 2017, 2017 Aug 22;7(1):9031.
63. Chang YC, Su CY, Chen MH, Chen CL, Chen WS, Hsiao M. Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to promotes colon cancer metastasis and is associated with poor prognosis. Mol Cancer. 2017 16:135.
64. Chien MH, Lee WJ, Chang WM, Chang YC, Lai TC, Chan DV, Sharma R, Lin YF, Hsiao M*. A Fas ligand (FasL)-fused humanized antibody against tumor-associated glycoprotein 72 (hcc49scFV-FasL) selectively exhibits the cytotoxic effect against oral cancer cells with a low FasL/Fas ratio. Mol Cancer Ther, 2017, 16(6), 1102-1113.
65. Chang WM, Lin YF, Su CY, Peng HY, Chang YC, Hsiao JR, Chen CL, Chang JY, Shieh YS, Hsiao M, Shiah SG. Parathyroid Hormone-Like Hormone is a Poor Prognosis Marker of Head and Neck Cancer and Promotes Cell Growth via RUNX2 Regulation. 2017, Sci Rep. 7:41131,
66. Chiang KC, Yeh TS, Huang CC, Chang YC, Juang HH, Chang CT, Pang JH, Chang JT, Takano M, Chen TC, Kittaka A, Hsiao M, Yeh CN. MART-10, the vitamin D analog, represses cholangiocarcinoma cell growth and high vitamin D receptor expression is linked with better prognosis for cholangiocarcinoma patients. 2017, Sci Rep. 7:43773,
67. Chang YC, Chi LH, Chang MW, Su CY, Lin YF, Chen CL, Chen MH, Chang PM, Wu AT, Hsiao M. Glucose Transporter 4 Promotes Head and Neck Cancer Metastasis through TRIM24-DDX58 Axis. J Hematol Oncol. 2017 10:11.
68. Chang WM, Lin YF, Su CY, Peng HY, Chang YC, Lai TC, Wu GH, Hsu YM, Chi LH, Hsiao JR, Chen CL, Chang JY, Shieh YS, Hsiao M, Shiah SG. Dysregulation of Runx2/Activin A axis upon miR376c downregulation promotes lymph node metastasis in head and neck squamous cell carcinoma. Cancer Res. 2016 Dec 15;76(24):7140-7150
69. Su CY, Chang YC, Yang CJ, Huang MS, Hsiao M. The opposite prognostic effect of NDUFS1 and NDUFS8 in lung cancer reflects the oncojanus role of mitochondrial complex I. Sci Rep. 2016 Aug 12;6:31357.
70. Chan YC, Chen CW, Chan MH, Chang YC, Chang WM, Chi LH, Yu HM, Lin YF, Tsai DP, Liu RS, Hsiao M. MMP2-sensing up-conversion nanoparticle for fluorescence biosensing in head and neck cancer cells. Biosens Bioelectron. 2016 Jun 15;80:131-9.
71. Chang YC, Su CY, Hsiao M. Therapeutic targeting of methylthioadenosine phosphorylase. Cancer Cell Microenviron. 2016 June; 3:e1322. Invited Review.
72. Lin TC, Su CY, Wu PY, Lai TC, Pan WA, Jan YH, Chang YC, Yeh CT, Chen CL, Ger LP, Chang HT, Yang CJ, Huang MS, Liu YP, Lin YF, Shyy JY, Tsai MD, Hsiao M. The nucleolar protein NIFK promotes cancer progression via CK1α/β-catenin in metastasis and Ki-67-dependent cell proliferation. Elife. 2016 Mar 17;5. pii: e11288. doi: 10.7554/eLife.11288.
73. Yang YF, Jan YH, Liu YP, Yang CJ, Su CY, Chang YC, Lai TC, Chiou J, Tsai HY, Lu J, Shen CN, Shew JY, Lu PJ, Lin YF, Huang MS, Hsiao M. Squalene synthase induces tumor necrosis factor receptor 1 enrichment in lipid rafts to promote lung cancer metastasis. Am J Respir Crit Care Med. 2014 Sep 15;190(6):675-87. doi: 10.1164/rccm.201404-0714OC. (Selected for Cover Story)
74. Su CY#, Chang YC#, Chan YC, Lin TC, Huang MS, Yang CJ, Hsiao M. MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients. Eur J Surg Oncol. 2014 Sep;40(9):1143-50. doi: 10.1016/j.ejso.2014.04.017. #co-1st author